You appear to be using an old web browser that may not properly display our pages. Our sites are built using standards compliant guidelines that require a more recent web browser such as:

Internet Explorer 6+
FireFox 1+
Netscape 6+

NewYork-Presbyterian Hospital
About Us Healthcare Services Health Info For Patients & Visitors For Health Professionals

New Hope for Those with High Blood Pressure



More than two-thirds of the 65 million Americans with high blood pressure require two or more anti-hypertensive medications to manage their condition, experts report. Many of these people also take medicines for high cholesterol and diabetes.

That makes for a heaping mound of pills to swallow every day.

"Anybody can take a few drugs for a few months, but these people have to be on drugs indefinitely," says Dr. John D. Bisognano, director of cardiac rehabilitation and clinical preventive cardiology at the University of Rochester Medical Center.

Research Brings New Treatment Avenues



But there is encouraging news on the horizon for people with high blood pressure. Easier-to-take medications and novel medications and devices promise to improve long-term hypertension management.

Basic research continues to sort out the causes of hypertension. And vigorous prevention initiatives aimed at sparing children from this chronic health problem breed hope for future generations of Americans.

Hypertension, often called "the silent killer," usually occurs without symptoms but remains a leading risk factor for stroke, heart attack, heart failure, and kidney disease. The only way to find out if you have it is to have a blood pressure reading.

High blood pressure is literally the force exerted as blood pumps into the arteries through the circulatory system and as the arteries resist the flow of blood, says the American Heart Association.

Systolic pressure, the "upper" number in a blood pressure reading, measures the force when your heart is contracting to pump out blood; the "lower" diastolic number reflects the pressure when the heart is resting between beats.

A normal blood pressure for adults is less than 120 mmHg (millimeters of mercury) over less than 80 mmHg, and a reading of 140/90 mmHg or higher is considered high, requiring medical intervention. In 2003, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, a panel convened by the federal government, added a new blood pressure category, called "prehypertension" - to put people on warning about the potential risk they face. Prehypertension is defined as a pressure of 120-139/80-89 mmHg.

For people with diabetes or kidney disease, the goal is to reduce blood pressure to 130/80 mmHg.

"One of the problems you run into is people who are at the highest risk - the people with diabetes and kidney disease - often require lots of medications to get their blood pressure down, because every medication gives you about a 10- to 15-point drop or so," Dr. Bisognano explains.

"If you're starting at 200 and need to go to 130, that's a lot of medications," he adds.

No single medication has proved to be the magic bullet for lowering blood pressure, so physicians typically rely on a number of different pharmaceuticals, including diuretics, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, beta blockers, and calcium channel blockers.

Pharmaceutical developers are responding to the need to make it easier for hypertensive patients to comply with medication regimens by developing new combination products.

In the future, there will be more fixed-dose combos of antihypertensive medications as well as pills that can treat more than one risk factor at a time, predicts LeadDiscovery, a United Kingdom-based research outfit.

Pfizer Inc. was the first to offer such a two-in-one product. In 2004, the company received approval from the US Food and Drug Administration (FDA) to begin marketing Caduet, a pill that contains both Norvasc for lowering high blood pressure and Lipitor for treating high cholesterol.

There are a few new agents in the pipeline that hold promise. One novel class of medications, called oral renin inhibitors, works by targeting an enzyme released by the kidneys that can affect blood pressure. The first of these agents to be introduced on the market is likely to be Aliskiren, a Novartis drug currently in phase III testing.

Meantime, even a device to keep blood pressure at bay is being tested. In March, physicians at the University of Rochester Medical Center were the first in the nation to implant the Rheos, a battery-operated generator that activates the body's natural blood pressure regulation systems.

Much like a pacemaker regulates heart rhythm, this device stimulates nerves in the carotid arteries to tell the brain to reduce blood pressure. Dr. Bisognano is part of the team that is testing the device.

Prevention Still Key



Still, preventing hypertension in the first place is a far better thing than having to rely on medicines or machines, clinicians agree. That is why the National Hypertension Association (NHA) has focused on basic research and education. NHA researchers have shown, for example, that salt-sensitive rats get high blood pressure when exposed to excess salt.

"But the salt resistant ones are not bothered by it at all; their kidneys get rid of it," notes Dr. William M. Manger, NHA chairman and clinical professor of medicine at New York University Medical Center. At least in salt-sensitive rats, it appears that excess salt to the brain causes hypertension, he said. How that will play out in humans is still unknown, but investigators are hopeful.

The NHA also sponsors VITAL (Values Initiative Teaching About Lifestyle), a rapidly expanding school-based initiative to change the lifestyle and behavior of young children.

It focuses on nutrition and exercise, a much broader agenda than hypertension alone. But it fills a critical gap, according to Dr. Manger, author of the not-yet-released book, Our Greatest Threats Protect Your Children and Yourself, focusing on preventing unhealthy lifestyles.

"I think this VITAL program is the best thing we could do for our nation," he says. Always consult your physician for more information.

Powered by Big Medium™

Contact Info
Jarrett Kroll
jkroll@med.cornell.edu


© NewYork-Presbyterian Hospital XML NYP Newsfeed | Ways to Give
Home | Disclaimer | Sitemap | Privacy Notice | Feedback